Résultats de recherche
View Jerry McMahon’s profile on LinkedIn, a professional community of 1 billion members. Dr. McMahon brings more than 30 years of exceptional biotechnology leadership, scientific…
- 500+
- 1.2K
- Jerry Mcmahon
Jerry McMahon, PhD Chief Executive Officer & President Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience.
7 sept. 2022 · STORM’s first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumors in 2022 and will be the first first-ever RME inhibitor molecule to enter clinical development.
7 sept. 2022 · 7 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board ...
7 sept. 2022 · STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer. Sep 07, 2022, 03:00 ET. Share this article. Industry veteran to lead STORM as it transitions into a clinical-stage...
7 sept. 2022 · STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director.
23 nov. 2022 · Dr Jerry McMahon, CEO of STORM Therapeutics, said: “This is a major milestone for STORM as we enter clinical development with our lead candidate STC-15 and continue progressing a pipeline targeting RNA modifying enzymes beyond METTL3.
